FDA Discusses Manufacturing Processes In ARB Medicines Impurities Update
Executive Summary
Manufacturers using processes at risk for impurities in ARB medicines are expected to complete tests to ensure that active ingredients and finished products are free of detectable levels of nitrosamine impurities, the FDA has directed.